Biomarkers play a key role in patients with testicular germ cell tumors in a variety of clinical contexts, including initial diagnosis, prognostication, monitoring treatment response, and posttreatment surveillance. Although the classic serum tumor markers for testicular germ cell tumors are essential for clinical management, the low sensitivity (particularly for seminoma and teratoma) and potential for false positives has spurred novel biomarker discovery and validation efforts. Here, we review the current state of serum-based biomarkers for testicular germ cell tumors, with a focus on the classic serum tumor markers and emerging class of microRNA markers.
The Urologic clinics of North America. 2023 Feb [Epub]
Jillian Egan, Keyan Salari
Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Center for Genitourinary Cancers, Massachusetts General Hospital Cancer Center, Boston, MA, USA; Cancer Program, The Broad Institute of MIT and Harvard, Cambridge, MA USA. Electronic address: .